GET DAILY SIGNALSPuma Biotechnology (PBYI) Posts Q3 Net Income Gain With Raised Guidance
Key Takeaways
- Puma Biotechnology reported third quarter 2026 GAAP net income of $6.0 million, or $0.11 per diluted share, with non-GAAP net income of $8.0 million, or $0.15 per share.
- Total revenue of $55.1 million came in below the consensus estimate of roughly $57.5 million, while NERLYNX net product revenue rose to $54.1 million from $53.6 million in the prior quarter.
- Management raised full-year 2026 net income guidance to $20–$22 million, up from a prior range of $17–$20 million.
- U.S. NERLYNX demand softened sequentially, with new prescriptions and patient enrollments declining despite year-over-year growth in overall demand.
- The company ended the quarter with $108.5 million in cash and marketable securities and no debt outstanding after retiring its remaining obligations earlier in the year.
Earnings Context and Why It Matters
Puma Biotechnology focuses on its approved HER2-positive breast cancer treatment NERLYNX along with a pipeline that includes the investigational Aurora Kinase A inhibitor alisertib. Since NERLYNX drives most of the company’s commercial activity, each earnings release gives a clear view of U.S. demand trends, reimbursement patterns, and pricing dynamics. The third quarter carried extra significance because management is balancing near-term profitability with higher research spending. After eliminating debt and strengthening the balance sheet, investors were watching closely to see whether commercial momentum could support the stock’s recent performance.
Reported Results
For the quarter ended September 30, 2026, total revenue reached $55.1 million, which included $54.1 million from NERLYNX net product sales and about $1.0 million in royalty revenue. NERLYNX product revenue rose from $53.6 million in the second quarter and from $51.9 million in the same quarter a year earlier, though the figure included roughly $3.6 million from ex-U.S. supply. GAAP net income came in at $6.0 million, or $0.11 per diluted share, compared with $8.2 million, or $0.16 per share, in the prior quarter. Non-GAAP net income, excluding stock-based compensation, was $8.0 million, or $0.15 per share. Earnings topped expectations, yet revenue fell short of the roughly $57.5 million consensus. Management narrowed full-year revenue guidance to $224–$227 million while lifting net income expectations to $20–$22 million. I also checked comparable names using Tickeron’s AI Screener to see how the results stacked up against peers.
Market Reaction and Investor Sentiment
Reaction to the report was mixed. The earnings beat and higher profitability outlook were offset by the revenue miss and softer U.S. demand signals. U.S. demand totaled 2,899 bottles, down 3% sequentially, while new prescriptions dropped 13% and patient enrollments fell 12%. A decline in sales calls, partly linked to territory vacancies, raised some execution questions. At the same time, a debt-free balance sheet, operating cash flow of $14.6 million, and stronger liquidity helped ease concerns about the demand softness.
Forward Outlook and Key Factors to Monitor
Attention now turns to whether demand can rebound in the fourth quarter, which is expected to carry a larger share of revenue and net income under the updated guidance. The company projected fourth-quarter total revenue of $67–$70 million, including royalty contributions, and net income of $10–$12 million. Gross-to-net adjustments were raised to 27.5%–28% for the full year and guided toward 28%–29% in the fourth quarter, reflecting a higher mix of Medicaid and 340B purchases. Any further increase could affect realized revenue even if volumes hold steady. The alisertib program remains a key area to watch, with a second trial now underway in advanced small cell lung cancer and additional data expected from existing studies in 2027. Higher research spending tied to these efforts contributed to the year-over-year decline in operating income. The company has also indicated interest in in-licensing or acquiring assets to broaden its portfolio beyond NERLYNX, which could become a notable catalyst in coming quarters. From what I see, monitoring these pipeline updates alongside commercial execution will be important.
AI Tools in My Research Process
I regularly turn to Tickeron’s AI-powered tools when reviewing earnings reports like this one. The platform helps surface comparable opportunities and technical patterns across the biotech sector, allowing me to place individual company results in broader context without spending hours on manual screening. It has become a practical part of my workflow for identifying names that share similar fundamentals or momentum characteristics.
Disclaimer
The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.
Contributor
Sergey Savastiouk, Ph.D. has a degree in Applied Mathematics from Moscow University and has extensive experience as an entrepreneur, investor, manager, and mathematician. His professional expertise is in applied mathematics, mathematical modeling, system and pattern analysis, and software and hardware system integration. He has served as the CEO of several hi-tech start-up companies and nonprofit organizations, which has given him proven capabilities in business strategy for high-tech start-up companies, market assessment, company formation, team building, product development, marketing, and sales. He has published numerous articles in journals and magazines on related fields. As a retail investor, he spent 15 years developing his proprietary trading and quantitative algorithms (now Tickeron’s A.I.), which brought him significant returns in trading the stock market. His current work and goal in founding Tickeron is to bring professional, sophisticated stock market analysis capabilities to retail investors via an easy-to-use interface.
PBYI's RSI Indicator recovers from overbought zone
The 10-day RSI Indicator for PBYI moved out of overbought territory on October 23, 2026. This could be a sign that the stock is shifting from an upward trend to a downward trend. Traders may want to look at selling the stock or buying put options. Tickeron's A.I.dvisor looked at 42 instances where the indicator moved out of the overbought zone. In 37 of the 42 cases the stock moved lower in the days that followed. This puts the odds of a move down at 88%.
Technical Analysis (Indicators)
Bearish Trend Analysis
The Momentum Indicator moved below the 0 level on November 02, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on PBYI as a result. In 76 of 97 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 78%.
The Moving Average Convergence Divergence Histogram (MACD) for PBYI turned negative on October 29, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 47 similar instances when the indicator turned negative. In 36 of the 47 cases the stock turned lower in the days that followed. This puts the odds of success at 77%.
PBYI moved below its 50-day moving average on November 05, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where PBYI declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 79%.
Bullish Trend Analysis
The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.
Following a +5.01% 3-day Advance, the price is estimated to grow further. Considering data from situations where PBYI advanced for three days, in 261 of 292 cases, the price rose further within the following month. The odds of a continued upward trend are 89%.
PBYI may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.
The Aroon Indicator entered an Uptrend today. In 210 of 231 cases where PBYI Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.
Fundamental Analysis (Ratings)
The Tickeron PE Growth Rating for this company is 2 (best 1 - 100 worst), pointing to outstanding earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Seasonality Score of 31 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.
The Tickeron Price Growth Rating for this company is 35 (best 1 - 100 worst), indicating steady price growth. PBYI’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is 44 (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 54 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.
The Tickeron Valuation Rating of 85 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (3.640) is normal, around the industry mean (2.788). P/E Ratio (18.434) is within average values for comparable stocks, (-0.376). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (133.911) among similar stocks. P/S Ratio (2.105) is also within normal values, averaging (440.869).
Notable companies
Industry description
Market Cap
High and low price notable news
Volume
Fundamental Analysis Ratings
The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows
Advertisement
General Information
operates as a development stage company which develops biopharmaceuticals used for the treatment of cancer
Industry Biotechnology
Advertisement